Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma

Takaaki Oba,Mark D. Long,Ken-ichi Ito,Fumito Ito

DOI: https://doi.org/10.1038/s41598-023-50062-y

IF: 4.6

2024-01-30

Scientific Reports

Abstract:Compelling evidence shows that the frequency of T cells in the tumor microenvironment correlates with prognosis as well as response to immunotherapy. However, considerable heterogeneity exists within tumor-infiltrating T cells, and significance of their genomic and transcriptomic landscape on clinical outcomes remains to be elucidated. Signaling lymphocyte activation molecule 6 ( SLAMF6 ) is expressed on intra-tumoral progenitor-exhausted T cells, which exhibit the capacity to proliferate, self-renew and produce terminally-exhausted T cells in pre-clinical models and patients. Here, we investigated the impact of SLAMF6 expression on prognosis in two immunologically different tumor types using publicly available databases. Our findings demonstrate that high SLAMF6 expression is associated with better prognosis, expression of TCF7 (encoding T-cell factor 1), and increased gene signatures associated with conventional type 1 dendritic cells and effector function of T cells in melanoma and breast cancer. Single-cell profiling of breast cancer tumor microenvironment reveals SLAMF6 expression overlaps CD8 T cells with a T-effector signature, which includes subsets expressing TCF7 , memory and effector-related genes, analogous to progenitor-exhausted T cells. These findings illustrate the significance of SLAMF6 in the tumor as a marker for better effector responses, and provide insights into the predictive and prognostic determinants for cancer patients.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem this paper attempts to address is the exploration of the impact of SLAMF6 (Signaling Lymphocytic Activation Molecule Family Member 6) expression in the tumor microenvironment of breast cancer and melanoma on immune status and clinical prognosis. Specifically, the researchers hypothesize that high expression of SLAMF6 is associated with higher immune activity and better clinical outcomes, and they aim to validate this hypothesis by analyzing data from public databases.

The research background points out that the quantity and quality of T cells in the tumor microenvironment are crucial for predicting the prognosis and treatment response of cancer patients. In particular, the presence density of CD8+ T cells is considered one of the important factors in predicting the effectiveness of chemotherapy and immune checkpoint inhibitors (ICI) treatment. However, although PD-1 expression is a marker of "exhausted" T cells, there is significant heterogeneity within PD-1+ CD8+ tumor-infiltrating lymphocytes (TILs), indicating that PD-1 expression levels alone are insufficient to comprehensively assess the functional state of T cells. Therefore, identifying biomarkers that can better predict patient response to ICI treatment is of great significance.

SLAMF6, as a potential marker, has been shown to be expressed in precursor exhausted T cells in both mice and humans. These cells have stem cell-like properties, capable of proliferating, self-renewing, and producing terminally exhausted T cells during ICI treatment. Based on this, the researchers further explored the expression of SLAMF6 in breast cancer and melanoma and its association with clinical prognosis, aiming to provide a basis for understanding the mechanisms of tumor immune response and developing new therapeutic strategies.